Episode Details
Back to Episodes
New mRNA Flu Shot Approved for Seniors | Ottawa News
Description
The FDA just approved a groundbreaking new flu vaccine called mFlusiva, using the same mRNA tech that revolutionized COVID-19 vaccines. Designed for adults 50 and older, it’s already showing promising results—27% more effective than standard shots in those 50–64, with strong early immune responses in seniors. Though side effects like soreness and fatigue are slightly more common, no major safety red flags emerged. After an initial setback, the FDA reversed course, paving the way for wider availability ahead of flu season—a major win for vulnerable populations and proof of science’s rapid adaptability.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/a551c4adfa2d2a5c